<DOC>
	<DOCNO>NCT00083408</DOCNO>
	<brief_summary>The purpose research study helpful combination thalidomide Pamidronate control multiple myeloma study side effect may experience .</brief_summary>
	<brief_title>Combination Bisphosphonate Anti-Angiogenesis Therapy With Pamidronate Thalidomide</brief_title>
	<detailed_description>Recently , laboratory research find thalidomide inhibit formation new blood vessel necessary growth spread cancer . In order grow increase size , tumor require new blood vessel supply necessary blood grow . If prevent new blood vessel feed tumor form use thalidomide might slow stop growth tumor . This concept call `` anti-angiogenesis '' . It hop thalidomide slow stop growth myeloma . However , guaranteed benefit take part study . The treatment receive may even harmful .</detailed_description>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Diphosphonates</mesh_term>
	<mesh_term>Thalidomide</mesh_term>
	<criteria>Patients must diagnosis Multiple myeloma poor hematopoietic reserve ( platelet count &lt; 100,000 OR inability collect adequate PBSC support autologous transplant ( 4X106 CD34+cells/kg OR WBC &lt; 2,000 ) Patients must eligible UARK 98035 Patients must least 6 week beyond previous chemotherapy All patient must inform investigational nature study must sign write informed consent accordance UAMS Human Research Advisory Committee federal guideline Prior bisphosphonate therapy within 30 day prior study entry Serum creatinine &gt; 5 mg/dl , ascites , serum direct bilirubin &gt; 2.5 mg/dl Prior plicamycin calcitonin within 2 week study entry Severe cardiac disease , unstable thyroid disease , epilepsy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2010</verification_date>
	<keyword>Multiple Myeloma</keyword>
	<keyword>Pamidronate</keyword>
	<keyword>Thalidomide</keyword>
	<keyword>refractory myeloma</keyword>
	<keyword>bisphosphonates</keyword>
	<keyword>Aredia</keyword>
</DOC>